Alpharma Expects FDA Reinspection Of Baltimore Site In Early 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
Alpharma expects an early 2005 reinspection by FDA of its liquid pharmaceuticals manufacturing plant that was the subject of an FDA-483 report earlier this year